At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Trading 01-10 14:09:54 EST
2.10
-0.03
-1.41%
High2.14Low2.05Vol117.79K
Open2.07D1 Closing2.13Amplitude4.23%
Mkt Cap53.20MTradable Cap44.00MTotal Shares25.33M
T/O246.25KT/O Rate0.56%Tradable Shares20.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
MAIA Biotechnology to Present at Biotech Showcase 2025
Business Wire  ·  01-10 22:45
MAIA Biotechnology to Present at Biotech Showcase 2025
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene
Dow Jones  ·  01-08
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene
MAIA Biotechnology enters clinical supply agreement with BeiGene for THIO
TIPRANKS  ·  01-07
MAIA Biotechnology enters clinical supply agreement with BeiGene for THIO
Maia Biotechnology: Under Deal, Maia to Sponsor, Fund Planned Clinical Trials & Beigene Will Provide Tislelizumab
THOMSON REUTERS  ·  01-07
Maia Biotechnology: Under Deal, Maia to Sponsor, Fund Planned Clinical Trials & Beigene Will Provide Tislelizumab
Maia Biotechnology Announces Clinical Supply Agreement With Beigene for Upcoming Phase 2 Trials in Three Cancer Indications
THOMSON REUTERS  ·  01-07
Maia Biotechnology Announces Clinical Supply Agreement With Beigene for Upcoming Phase 2 Trials in Three Cancer Indications
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Business Wire  ·  01-07
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
BRIEF-MAIA Biotechnology Increased Maximum Offering Price Of Shares Of Common Stock Issuable Under At Market Offering Agreement To $30 Million
Reuters  ·  2024-12-24
BRIEF-MAIA Biotechnology Increased Maximum Offering Price Of Shares Of Common Stock Issuable Under At Market Offering Agreement To $30 Million
Maia Biotechnology : Increased Maximum Offering Price of Shares of Common Stock Issuable Under at Market Offering Agreement to $30 Mln
THOMSON REUTERS  ·  2024-12-24
Maia Biotechnology : Increased Maximum Offering Price of Shares of Common Stock Issuable Under at Market Offering Agreement to $30 Mln
Maia Biotechnology Announces Director Participation in Recent Private Placement Closings
THOMSON REUTERS  ·  2024-12-19
Maia Biotechnology Announces Director Participation in Recent Private Placement Closings
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
Business Wire  ·  2024-12-19
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires Live  ·  2024-12-17
Sector Update: Health Care Stocks Slide Late Afternoon
Sector Update: Health Care Stocks Decline Monday Afternoon
MT Newswires Live  ·  2024-12-17
Sector Update: Health Care Stocks Decline Monday Afternoon
MAIA Biotechnology granted FDA rare pediatric disease designation for THIO
TIPRANKS  ·  2024-12-17
MAIA Biotechnology granted FDA rare pediatric disease designation for THIO
MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas
MT Newswires Live  ·  2024-12-16
MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas
Maia Biotechnology Granted FDA Rare Pediatric Disease Designation for Thio as a Treatment for Pediatric High-Grade Gliomas
THOMSON REUTERS  ·  2024-12-16
Maia Biotechnology Granted FDA Rare Pediatric Disease Designation for Thio as a Treatment for Pediatric High-Grade Gliomas
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Business Wire  ·  2024-12-16
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
MAIA Biotechnology to sell 507,364 shares at $1.872 in private placement
TIPRANKS  ·  2024-12-10
MAIA Biotechnology to sell 507,364 shares at $1.872 in private placement
Maia Biotechnology Announces Private Placement of Approximately $950,000
THOMSON REUTERS  ·  2024-12-10
Maia Biotechnology Announces Private Placement of Approximately $950,000
MAIA Biotechnology Announces Private Placement of Approximately $950,000
Business Wire  ·  2024-12-10
MAIA Biotechnology Announces Private Placement of Approximately $950,000
Amazon Bedrock Empowers Customers to Accelerate Generative AI Adoption with More Than 100 New Models and Powerful New Capabilities for Inference and Working with Data
Business Wire  ·  2024-12-05
Amazon Bedrock Empowers Customers to Accelerate Generative AI Adoption with More Than 100 New Models and Powerful New Capabilities for Inference and Working with Data

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--